On July 3, 2025 Congress passed, and on July 4, 2025 President Trump signed into law, the One Big Beautiful Bill Act (OBBB), which extends various expiring tax provisions from the Tax Cuts and Jobs Act and introduces a variety
Life Sciences Perspectives
Life Sciences Perspectives, published by Goodwin Procter, focuses on legal and regulatory developments affecting the life sciences sector. The blog covers topics such as pharmaceutical and biotechnology transactions, regulatory compliance for drugs, biologics, medical devices, diagnostics, and laboratory testing. It also addresses antitrust issues, healthcare fraud enforcement, data privacy regulations like the EU Data Act, and FDA programs impacting drug development and approval. The blog provides updates on policy changes, enforcement trends, and strategic considerations for companies and investors operating in the life sciences and medtech industries.
Latest from Life Sciences Perspectives - Page 2
Biotech M&A and Partnerships: Innovation and Deal-Making in Challenging Markets
As part of Goodwin’s exclusive programming during the BIO International Convention in Boston, we invite you to join us for a session spotlighting the evolving world of M&A and strategic partnerships in a rapidly shifting biotech landscape.
Through a dynamic…
Maximizing IP Value: Strategize Now to Win Later
As part of Goodwin’s exclusive programming during the BIO International Convention in Boston, we invite you to join us for a focused discussion on how biotech and pharma companies can protect and maximize the value of their intellectual property. In…
From Europe to the US: Crossing the Atlantic for Capital & Strategic Growth
As part of our week of premier programming during the BIO International Convention in Boston, we’re bringing together industry leaders, investors, and strategic advisors for an engaging session on how European biotechs can successfully expand into the US market.
This…
Navigating China-Related Transactions: Legal and Strategic Considerations
As part of Goodwin’s week of exclusive programming during the BIO International Convention in Boston, we’re excited to invite you to a session focused on China-based NewCos and the dynamics of cross-border dealmaking. China continues to be a dynamic hub…
AI & Drug Discovery Symposium: Revolutionizing the Future of Medicine
Jumpstart your week with a deep dive into the future of medicine as part of Goodwin’s exclusive programming during the BIO International Convention in Boston. Join us for a dynamic symposium where industry leaders and AI pioneers come together to…
Antitrust Life Sciences Quarterly Update 2025 Q1
While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the antitrust space in the first 100 days of the Trump administration. The Federal Trade Commission (FTC) under…
Most Favored Nation Drug Pricing Executive Order Resurrects Prior President Trump Policy
On May 12, 2025, President Trump signed the most recent Executive Order on drug pricing, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. This latest Executive Order simultaneously pushes key stakeholders (i.e. foreign governments and drug manufacturers) to modify their…
Charting a Conditional Approval Pathway for Rare Disease Drugs – A Top Priority for a Revamped FDA?
On April 18, U.S. Food and Drug Administration (FDA) Commissioner Marty Makary announced plans to roll-out a new approval pathway for rare disease drugs. Commissioner Makary’s comments build on sentiments expressed across both the patient community and industry that rare…
A Look Ahead in Life Sciences: What We Are Tracking in the Second Quarter of 2025 and Beyond
To help companies and investors navigate the many evolving and emerging laws and regulations across pharmaceuticals, biologics, medical devices, diagnostics, and laboratory testing, our Life Sciences Regulatory & Compliance team has provided an overview of key developments. We update and…